Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Thomas Luger, Mark Boguniewicz, Warner Carr, Michael Cork, Mette Deleuran, Lawrence Eichenfield, Philippe Eigenmann, Regina Fölster-Holst, Carlo Gelmetti, Harald Gollnick, Eckard Hamelmann, Adelaide A. Hebert, Antonella Muraro, Arnold P. Oranje, Amy S. Paller, Carle Paul, Luis Puig, Johannes Ring, Elaine Siegfried, Jonathan M. SpergelGeorg Stingl, Alain Taieb, Antonio Torrelo, Thomas Werfel, Ulrich Wahn

Research output: Contribution to journalArticlepeer-review


Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (

Original languageEnglish
Pages (from-to)306-315
Number of pages10
JournalPediatric Allergy and Immunology
Issue number4
Publication statusPublished - Jun 1 2015


  • Atopic dermatitis
  • Eczema
  • Infants
  • Paediatric
  • Pimecrolimus
  • Safety
  • Tacrolimus
  • Topical calcineurin inhibitors
  • Topical corticosteroids

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health
  • Immunology


Dive into the research topics of 'Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants'. Together they form a unique fingerprint.

Cite this